| 1. |
New guidelines for the prevention and treatment of thrombosis have been released by the American College of Chest Physicians |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1456,
2004,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 2. |
The UK National Institute for Clinical Excellence (NICE) has issued guidance to the NHS in England and Wales on the use of immunosuppressant therapy for kidney transplantation among adults. |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1456,
2004,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 3. |
Etanercept, efalizumab repair QOL in chronic plaque psoriasis |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1456,
2004,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 4. |
Infliximab cost effective for ankylosing spondylitis in the UK |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1456,
2004,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 5. |
Oral bexarotene promising for chronic plaque psoriasis |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1456,
2004,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 6. |
Dronedarone rates highly for atrial fibrillation |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1456,
2004,
Page 8-8
A Prakash,,
Preview
|
|
摘要:
Dronedarone is effective and well tolerated in maintaining sinus rhythm in patients with atrial fibrillation (AF) or atrial flutter (AFL), according to the results of one of the largest clinical trial programmes conducted on the maintenance of sinus rhythm. The results of the EURIDIS and ADONIS trials, presented at the 26th Annual Congress of the European Society of Cardiology (ESC) [Munich, Germany; August-September 2004] showed that dronedarone was significantly more effective than placebo in preventing the recurrence of asymptomatic and symptomatic AF and AFL. The tolerability profile of the drug was similar to that of placebo and there was no incidence of Torsade de Pointes in the 12-month follow-up period.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 7. |
Radiotherapy + UFT advantageous for operable rectal cancer |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1456,
2004,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 8. |
Atazanavir an alternative to efavirenz in HIV infections |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1456,
2004,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 9. |
Rosuvastatin leads the way in metabolic syndrome |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1456,
2004,
Page 11-12
S Sullivan,,
Preview
|
|
摘要:
Rosuvastatin [Crestor] has been shown to reduce risk factors for cardiovascular disease in patients with metabolic syndrome, according to a study presented at the 40th Annual Meeting of the European Association for the Study of Diabetes (EASD) [Munich, Germany; September 2004]. Results from the COMETS study showed that rosuvastatin reduced LDL-cholesterol (LDL-C) and increased HDL-cholesterol (HDL-C) levels in patients with metabolic syndrome to a significantly greater extent than atorvastatin. Furthermore, a higher proportion of rosuvastatin recipients achieved recommended LDL-C goals, compared with patients receiving atorvastatin.
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
| 10. |
The MVP*chemotherapy regimen is effective as palliative therapy in patients with inoperable malignant mesothelioma, |
| |
Inpharma Weekly,
Volume &NA;,
Issue 1456,
2004,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2004
数据来源: ADIS
|
首页
